{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:57Z","timestamp":1761894777837,"version":"3.35.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T00:00:00Z","timestamp":1221523200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s10067-008-1007-9","type":"journal-article","created":{"date-parts":[[2008,9,15]],"date-time":"2008-09-15T10:46:32Z","timestamp":1221475592000},"page":"167-172","source":"Crossref","is-referenced-by-count":25,"title":["Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors"],"prefix":"10.1007","volume":"28","author":[{"given":"Inbal","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Avnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Freud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abu-Shakra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,16]]},"reference":[{"key":"1007_CR1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"J Gomez-Reino","year":"2007","unstructured":"Gomez-Reino J, Carmona L, Descalzo M (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756\u2013761","journal-title":"Arthritis Rheum"},{"key":"1007_CR2","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","volume":"162","author":"AG Bean","year":"1999","unstructured":"Bean AG, Roach DR, Briscoe H et al (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection which is not compensated for by lymphotoxin. J Immunol 162:3504\u20133511","journal-title":"J Immunol"},{"key":"1007_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","volume":"2","author":"JL Flynn","year":"1995","unstructured":"Flynn JL, Goldstein MM, Chan J et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561\u2013572","journal-title":"Immunity"},{"key":"1007_CR4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J (2001) Tuberculosis associated with infliximab, a tumor necrosis factor\u2013\u03b1-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"1007_CR5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2005.040055","volume":"65","author":"BE Joven","year":"2006","unstructured":"Joven BE, Almodovar R, Galindo M, Mateo I, Pablos JL (2006) Does anti-tumour necrosis factor a treatment modify the tuberculin PPD response? Ann Rheum Dis 65:699","journal-title":"Ann Rheum Dis"},{"key":"1007_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/ajrccm.159.1.9801120","volume":"159","author":"D Menzies","year":"1999","unstructured":"Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159:15\u201321","journal-title":"Am J Respir Crit Care Med"},{"key":"1007_CR7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","volume":"64","author":"D Ponce de Leon","year":"2005","unstructured":"Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360\u20131361","journal-title":"Ann Rheum Dis"},{"key":"1007_CR8","first-page":"474","volume":"34","author":"G Hatemi","year":"2006","unstructured":"Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H (2006) Infliximab does not suppress the tuberculin skin test (purified protein derivative. J Rheumatol 34:474\u2013480","journal-title":"J Rheumatol"},{"key":"1007_CR9","first-page":"212","volume":"146","author":"I Fuchs-Polishuk","year":"2007","unstructured":"Fuchs-Polishuk I, Avnon LS, Abu shakra M (2007) Tuberculosis among patients treated with TNF-alpha blockers. Harefuah 146:212\u2013218","journal-title":"Harefuah"},{"key":"1007_CR10","first-page":"235","volume":"146","author":"O Elkayam","year":"2007","unstructured":"Elkayam O, Balbir-gurman A, Lidgi M, Rahav G, Weiler-Ravel D (2007) Guidelines of the Israeli association of rheumatology for prevention of tuberculosis in patients treated with TNF-alpha blockers. Harefuah 146:235\u2013237","journal-title":"Harefuah"},{"key":"1007_CR11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/ajrccm.162.4.9912048","volume":"162","author":"K Al Zahrani","year":"2000","unstructured":"Al Zahrani K, Al Jahdali H, Menzies D (2000) Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease. Am J Respir Crit Care Med 162:1419\u20131422","journal-title":"Am J Respir Crit Care Med"},{"key":"1007_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","volume":"2","author":"SW Mow","year":"2004","unstructured":"Mow SW, Abreu-martin MT (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol and Hepatol 2:309\u2013313","journal-title":"Clin Gastroenterol and Hepatol"},{"key":"1007_CR13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thorax.57.9.804","volume":"57","author":"L Wang","year":"2002","unstructured":"Wang L, Turner MO, Elwood RK et al (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurement. Thorax 57:804\u2013809","journal-title":"Thorax"},{"key":"1007_CR14","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Resp Crit Care Med 161:S221\u2013247","journal-title":"Am J Resp Crit Care Med"},{"key":"1007_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","volume":"60","author":"L Berg","year":"2001","unstructured":"Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L (2001) Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60:133\u2013139","journal-title":"Ann Rheum Dis"},{"key":"1007_CR16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","volume":"62","author":"J Vanhoof","year":"2003","unstructured":"Vanhoof J, Landewe S, Van Wijngaerden Geusens P (2003) High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62:1241\u20131242","journal-title":"Ann Rheum Dis"},{"key":"1007_CR17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(00)02742-2","volume":"356","author":"P Andersen","year":"2000","unstructured":"Andersen P, Munk ME, Pollock JM, Doherty TM (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356:1099\u20131103","journal-title":"Lancet"},{"issue":"RR15","key":"1007_CR18","first-page":"49","volume":"54","author":"G Mazurek","year":"2005","unstructured":"Mazurek G, Jereb J, Lobue P, Iademerco M, Metchock B, Vernon A (2005) Guidelines or using the QuantiFERON-TB test for detecting Mycobacterium tuberculosis infection, United States. MMWR Morb mortal Wkly Recomm Rep 54(RR15):49\u201355","journal-title":"MMWR Morb mortal Wkly Recomm Rep"},{"key":"1007_CR19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(06)68579-6","volume":"367","author":"G Ferrara","year":"2006","unstructured":"Ferrara G, Losi M, D\u2019Amico R et al (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367:1328\u20131334","journal-title":"Lancet"},{"key":"1007_CR20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/rheumatology\/kem064","volume":"46","author":"A Pratt","year":"2007","unstructured":"Pratt A, Nicholl K, Kay L (2007) Use of QuantiFERON TB Gold test as part of a screening program in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle experience. Rheumatology 46:1035\u20131036","journal-title":"Rheumatology"},{"key":"1007_CR21","unstructured":"Centers for Diseases Control and Prevention. Guidelines for Using the QuantiFERON\u00ae-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection. http:\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5202a2.htm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-1007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-008-1007-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-1007-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T23:02:32Z","timestamp":1738364552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-008-1007-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,16]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s10067-008-1007-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2008,9,16]]}}}